Clinical trials: Chronic Disease Management
Chronic Heart Failure
A Clinical Trial to Evaluate the HeartWare™ Ventricular Assist System (ENDURANCE SUPPLEMENTAL TRIAL)
This is a prospective, randomized, controlled, unblinded, multi-center evaluation of safety and efficacy in patients implanted with a HeartWare® HVAD who receive improved blood pressure management.
- Trial name
- DT2 (NCT01966458)
- Testing
- HeartWare® VAS (HVAD), Control LVAD
- Where
- 47 sites in United States
- Volunteers
- 494 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Type 2 Diabetes Mellitus
A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)
This study will evaluate the efficacy and safety of ertugliflozin (MK-8835/PF-04971729) in participants with Type 2 diabetes mellitus with Stage 3 Chronic Kidney Disease (CKD) who have inadequate glycemic control on background…
- Trial name
- NCT01986855
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 10 mg
- Volunteers
- 468 people
- Sponsor
- Merck Sharp & Dohme LLC
Hematological Malignancies
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogneic signal is present.
- Trial name
- NCT00438178
- Testing
- Obatoclax mesylate (GX15-070MS)
- Where
- 3 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Gemin X
Chronic Myeloid Leukemia (CML)
Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population
The purpose of this study is to examine the healthcare costs among patients with CML receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured population.
- Trial name
- NCT02363868
- Where
- United States
- Volunteers
- 186 people
- Sponsor
- Bristol-Myers Squibb
Kidney Disease
Aranesp® Monthly Preference Study - 2
The purpose of this study was to evaluate subject preference for Aranesp® administered once monthly (i.e., every 4 weeks (Q4W)) or Procrit® administered once weekly (QW).
- Trial name
- NCT00117078
- Testing
- Aranesp®
- Sponsor
- Amgen
HCV Infection
Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection
This study is to determine the antiviral efficacy of sofosbuvir (SOF)/ledipasvir (LDV) fixed-dose combination (FDC) with and without ribavirin (RBV), and to evaluate the safety and tolerability of each regimen as assessed by…
- Trial name
- NCT01965535
- Testing
- LDV/SOF, RBV
- Where
- 19 sites in France
- Volunteers
- 155 people
- Sponsor
- Gilead Sciences
Pulmonary Disease, Chronic Obstructive
Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).
Evaluate whether the effect of inhaled tiotropium bromide on the change in trough forced expiratory volume (FEV1), compared to placebo in patients with chronic obstructive pulmonary disease (COPD), is affected by smoking status.
- Trial name
- NCT00239408
- Testing
- Pulmonary function Testing, tiotropium bromide
- Where
- 33 sites in Portugal
- Volunteers
- 311 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Evaluation of the Effect of Roflumilast in Hyperinflated COPD Patients Using Functional Respiratory Imaging
In this study the efficacy of Roflumilast in addition to LAMA/LABA therapy will be assessed using Functional Respiratory Imaging.
- Trial name
- NCT02451540
- Testing
- HRCT scan, Roflumilast
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- FLUIDDA nv
Chronic Hepatitis C Infection, Hepatitis C
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
The purpose of this study is to evaluate the antiviral activity, safety, and pharmacokinetics of ABT-450 with ritonavir (ABT-450/r) dosed in combination with ABT-333 (also known as dasabuvir) and ribavirin (RBV) in…
- Conditions
- Chronic Hepatitis C Infection, Hepatitis C, Hepatitis C Virus
- Trial name
- NCT01306617
- Testing
- ABT-450, ABT-333, ribavirin
- Where
- 11 sites in United States
- Volunteers
- 50 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Leukemia, Lymphocytic, Chronic, B-Cell
DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia
Phase 2 study to assess the efficacy of INVAC-1, a DNA plasmid encoding a modified human telomerase reverse transcriptas (hTERT) protein, at a dose of 800 µg for 6 cycles 4 weeks apart on Minimal Residual Disease (MRD)…
- Trial name
- NCT03265717
- Testing
- INVAC-1
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Invectys
Chronic Obstructive Pulmonary Disease
Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect by REGEND001 Cell Therapy
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow.
- Trial name
- NCT05638776
- Testing
- REGEND001 cell therapy
- Where
- 8 sites in China
- Volunteers
- 58 people
- Sponsor
- Regend Therapeutics
Heart Failure, Congestive
Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.
The purpose of this study is to evaluate the efficacy of a 24-hour infusion of levosimendan compared with placebo in the treatment of decompensated chronic heart failure.
- Trial name
- NCT00048425
- Testing
- Levosimendan
- Where
- 166 sites in United States, Australia and 2 more
- Volunteers
- 600 people
- Sponsor
- Abbott
Hepatitis C
A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response
This study is being conducted to learn more about the safety and effect of telaprevir in combination with peginterferon alfa-2a (PEG-IFN) and ribavirin (RBV) in participants with hepatitis C who have never been treated for their…
- Trial name
- NCT00758043
- Testing
- telaprevir, ribavirin, peginterferon alfa-2a
- Where
- 82 sites in United States, Belgium and 2 more
- Volunteers
- 540 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD
This efficacy and safety study compares four different combinations of blinded inhaled steroid treatments on top of open-label tiotropium and salmeterol in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00535366
- Testing
- Tiotropium, Salmeterol, Fluticasone
- Where
- 12 sites in Belgium, Denmark and 2 more
- Volunteers
- 103 people
- Sponsor
- Boehringer Ingelheim
HCV Infection
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
The primary purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and activity of escalating, multiple, oral doses of GS-5885 in subjects with chronic genotype 1 Hepatitis C Virus (HCV) infection.
- Trial name
- NCT01193478
- Testing
- GS-5885
- Where
- 13 sites in United States
- Volunteers
- 71 people
- Sponsor
- Gilead Sciences
Sleep Initiation and Maintenance Disorders
Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia
The purpose of this study is to determine the efficacy and safety of ramelteon, once daily (QD), taken in combination with Gabapentin for treating insomnia.
- Trial name
- NCT00755508
- Testing
- Ramelteon and gabapentin, Ramelteon, Gabapentin
- Volunteers
- 378 people
- Sponsor
- Takeda
Chronic Hepatitis B
A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B
This is a randomized, double-blinded, placebo-controlled, phase IIa study to evaluate safety and efficacy of TQ-A3334 combined with entecavir in the untreated or HBV DNA negative subjects with Chronic Hepatitis B.
- Trial name
- NCT04180150
- Testing
- TQ-A3334, Entecavir Tablet
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Schizophrenia
SWitching to Abilify Trial (SWAT)
To evaluate the efficacy, safety and tolerance of an 12 and 26-week aripiprazole administration
- Trial name
- NCT00304616
- Testing
- Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Diabetes
Effect of Platelet Concentrate in Treatment of Diabetic Ulcers
Autologous platelet concentrate will enhance the rate of healing of chronic diabetic wounds
- Trial name
- NCT00215735
- Testing
- debridement, dressing, and APC
- Where
- 9 sites in United States
- Sponsor
- Harvest Technologies
Chronic Plaque Psoriasis
ChangE From Any Systemic psoriasiS therapY to Raptiva
To assess the safety of transitioning subjects to Raptiva therapy from standard oral systemic or phototherapy by overlapping with Raptiva whilst tapering the initial systemic therapy or phototherapy dose.
- Trial name
- EASY (NCT00697593)
- Testing
- Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.